Intract Pharma Limited

Core Focus and Scientific Rationale

The central problem Intract Pharma addresses is that many valuable therapeutic molecules — particularly proteins, peptides, antibodies, and other biologics — are poorly suited to oral administration. When taken by mouth, these molecules are frequently degraded by stomach acid and digestive enzymes before they can exert their therapeutic effect, or they simply cannot be absorbed effectively across the gut wall. As a result, many biologic medicines must be administered by injection or infusion, which affects patient convenience, compliance, and comfort.

Intract Pharma's work is built around delivery technologies designed to protect sensitive drug molecules as they travel through the harsh environment of the stomach and upper intestine, and to release them at specific points in the GI tract — most notably the colon. Targeting the colon is especially valuable for treating diseases that affect the lower gut directly, such as inflammatory bowel disease (IBD), and for approaches where local delivery can reduce systemic side effects.

Key Technologies and Platforms

Intract Pharma has developed proprietary formulation and drug-delivery platform technologies aimed at controlling where and how a drug is released within the gastrointestinal tract. These platforms are the foundation of the company's product and service offerings.

Colonic and Targeted GI Delivery

A key element of Intract Pharma's technology portfolio is centred on site-specific delivery to the colon. This involves coating and formulation approaches that respond to the physiological conditions found in different parts of the digestive system — such as changes in pH, the presence of particular enzymes, or the microbial environment of the gut — to trigger drug release at the desired location. By ensuring that a drug is released in the colon rather than being absorbed or degraded earlier, the technology enables local treatment of colonic diseases and improved therapeutic targeting.

Oral Biologics Delivery

Building on its GI targeting expertise, the company has focused on enabling the oral delivery of biologic drugs, including antibodies and other large molecules. This is a particularly challenging and high-value area of pharmaceutical science, because the ability to deliver biologics orally rather than by injection could transform how many chronic conditions are treated. The company's approach seeks to protect biologic molecules from degradation and to deliver them intact to the target tissue within the gut.

Formulation and Coating Technologies

Underpinning these applications is a body of expertise in advanced formulation science, including specialised coatings, controlled-release systems, and stabilisation approaches. These techniques allow the company and its partners to convert molecules that would traditionally require parenteral (injectable) administration into candidates for oral dosage forms.

Products and Services

Intract Pharma primarily operates as a technology and development partner within the pharmaceutical industry. Rather than being solely a marketer of finished consumer medicines, the company offers its expertise and platforms to help other organisations develop new products. Its offerings typically include:

• Drug delivery platform technologies: Licensing and application of proprietary systems for targeted GI and colonic delivery, as well as oral biologics delivery.

• Formulation development services: Working with client molecules to design and develop oral formulations tailored to reach specific parts of the digestive tract or to protect sensitive drugs from degradation.

• Collaborative research and development: Partnering with pharmaceutical and biotechnology companies to co-develop oral versions of injectable drugs or to improve the delivery of existing therapeutics.

• Internal pipeline development: Advancing the company's own drug candidates and reformulated products that leverage its delivery technologies, often targeting gastrointestinal diseases such as inflammatory bowel disease.

Therapeutic Areas of Interest

The primary therapeutic focus for Intract Pharma's technologies is gastrointestinal disease, where localised delivery offers clear clinical advantages. Inflammatory bowel disease — encompassing conditions such as Crohn's disease and ulcerative colitis — is a natural application, as delivering an anti-inflammatory or biologic agent directly to affected colonic tissue may improve efficacy while limiting exposure elsewhere in the body.

Beyond local GI treatment, the broader ambition of oral biologics delivery extends the potential reach of the company's technology to conditions currently treated by injectable biologics, where an effective oral alternative could offer significant patient benefits.

Business Model and Partnerships

Intract Pharma's business model relies heavily on collaboration and partnership. As a specialist technology company, it creates value by applying its scientific capabilities to the challenges faced by larger pharmaceutical developers. Through licensing arrangements, joint development programmes, and service-based engagements, the company enables partners to bring difficult molecules into oral dosage forms. This partnership-driven approach is common among drug delivery specialists, allowing the company to contribute its niche expertise across multiple therapeutic programmes without needing to commercialise every product itself.

Position in the Life Sciences Sector

Within the UK's strong life sciences ecosystem, Intract Pharma represents the kind of focused, technology-led enterprise that supports innovation across the pharmaceutical value chain. Its emphasis on oral drug delivery aligns with broader industry trends toward improving patient convenience, adherence, and outcomes, particularly for chronic conditions requiring long-term treatment. By addressing the technical barriers to oral administration of biologics and enabling precise targeting within the gastrointestinal tract, the company contributes to a field of research with substantial clinical and commercial significance.

Summary

Intract Pharma Limited is a UK drug delivery company specialising in technologies that enable targeted release of therapeutics within the gastrointestinal tract and the oral delivery of biologic drugs. Through its proprietary formulation and coating platforms, the company works to overcome the natural barriers that prevent effective oral administration of sensitive molecules, with a strong emphasis on colonic delivery and the treatment of gastrointestinal diseases such as inflammatory bowel disease. Operating largely as a development and technology partner to the wider pharmaceutical industry, Intract Pharma combines scientific expertise in pharmaceutics with a clear focus on improving how medicines are delivered to patients.